Skip to ContentSkip to Navigation
About us Latest news News News articles

TRAIL-receptor and proteasome targeted therapies in non-small cell lung cancer

20 April 2011

PhD ceremony: Ms. J.H. Stegehuis, 13.15 uur, Academiegebouw, Broerstraat 5, Groningen

Title: TRAIL-receptor and proteasome targeted therapies in non-small cell lung cancer

Promotor(s): prof. E.G.E. de Vries

Faculty: Medical Sciences


The natural occurring protein TRAIL is important in the battle against cancer. TRAIL binds to healthy cells where it but does not cause damage, whereas binding to tumour cells may lead to their elimination. Various TRAIL-receptor targeting drugs are likely to increase the activity of anticancer drugs, as has been shown in preclinical studies. The aim of this thesis was to explore the combined use of TRAIL-receptor targeting therapies with the anticancer drug bortezomib in preclinical models of non-small cell lung cancer. It was found that the combination strongly induces apoptosis. Bortezomib could overcome tumour cell preferences for TRAIL-receptor1 or TRAIL-receptor2 apoptosis and enhance apoptosis induced via both receptors in the cancer cells. Examination of the underlying mechanisms revealed that bortezomib could sensitize TRAIL-induced apoptosis at the level of DISC (at the membrane) as well as at the level of the mitochondria (intracellular). Bortezomib had an effect on TRAIL-receptor endocytosis, although its functionality remains unknown.


Last modified:13 March 2020 01.12 a.m.
View this page in: Nederlands

More news

  • 29 November 2023

    UMCG opent nieuwe faciliteit voor microbioomonderzoek 

    Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...

  • 28 November 2023

    Science: more exciting than showbiz

    Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...

  • 13 November 2023

    UMCG beantwoordt vragen patiënten met hulp van AI

    Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...